Article Text

Download PDFPDF

Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
  1. Harry L A Janssen1,
  2. Milan J Sonneveld1,
  3. Maurizia R Brunetto2
  1. 1Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
  2. 2Hepatology Unit, University Hospital of Pisa, Pisa, Italy
  1. Correspondence to Professor H L A Janssen, Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, 's Gravendijkwal 230, Room Ha206, 3015 CE Rotterdam, The Netherlands; h.janssen{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Chronic hepatitis B infection is a global health problem affecting more than 350 million people worldwide.1 Prolonged liver inflammation caused by active infection with the hepatitis B virus (HBV) may result in progression to liver fibrosis, cirrhosis and ultimately hepatocellular carcinoma and death.1

Since the 1960s, hepatitis B virus surface antigen (HBsAg) has been the hallmark of HBV infection with concentrations reaching several hundred micrograms per millilitre.2 Recently, studies with newly available automated quantitative assays have shown that serum HBsAg levels vary significantly during the different phases of chronic HBV infection and are inversely correlated with the immune control of HBV: the higher control, the lower HBsAg level.3–6 These findings are consistent with the hypothesis that serum levels of HBsAg reflect the complex interplay between virus and immune system and provide complementary information to viral load as measured using HBV DNA levels. In fact, serum HBsAg levels result not only from virions (42 nm, Dane particles) but mainly from non-infectious HBsAg particles (20 nm diameter filaments of variable length and 20–22 nm spheres) which do not contain viral nucleic acids and exceed virions by a factor ranging between 102 and 105. The ratios between defective HBsAg particles and virions are not stable, but change over time. Filaments and spherical particles are produced in large excess in highly viraemic hepatitis B ‘e’ antigen (HBeAg)-positive carriers. While filaments decline in parallel with virions, spherical particles remain in moderate excess in low viraemic HBeAg-negative carriers.7 8 Thus, HBsAg production varies both quantitatively and qualitatively over time and appears to be dynamically regulated during different phases of the infection. HBsAg derives mainly from the intrahepatic viral minichromosome (cccDNA) by translation of specific RNAs that are distinct from pregenomic RNA, and HBsAg synthesis follows a pathway that is distinct from …

View Full Text


  • Competing interests HLAJ received grants from and is a consultant for Bristol Myers Squibb, Gilead Sciences, Novartis, Roche and Merck. MRB is on the speaker bureau/advisor of Abbott, BMS, Gilead, Hoffmann-la Roche and Merck. MJS has nothing to disclose.

  • Provenance and peer review Commissioned; externally peer reviewed.